Bruce L. Levine

faculty photo
Barbara and Edward Netter Professor in Cancer Gene Therapy
Abramson Cancer Center of the University of Pennsylvania (Member), Abramson Cancer Center of the University of Pennsylvania (Member)
Deputy Director - Technology Innovation and Assessment, Center for Cellular Immunotherapies, University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine
Founding Director, Clinical Cell and Vaccine Production Facility, University of Pennsylvania Department of Pathology and Laboratory Medicine, Perelman School of Medicine and Abramson Cancer Center
Department: Pathology and Laboratory Medicine

Contact information
Center for Cellular Immunotherapies
Smilow 8-114
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-746-1481
Graduate Group Affiliations
Education:
B.A. (Major-Biology, Minor-History)
The University of Pennsylvania , 1984.
Ph.D. (Immunology and Infectious Diseases)
The Johns Hopkins University, 1992.
Permanent link
 

Description of Research Expertise

Immunology, Cell and Gene Therapy

Description of Other Expertise

Good Manufacturing Practices

Description of Itmat Expertise

Dr. Levine's interests include cell, gene, and biologic therapy clinical trial development, manufacturing, and testing and lymphocyte growth, activation and senescence.

Selected Publications

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC: Reducing Ex Vivo Culture Improves the Anti-leukemic Activity of Chimeric Antigen Receptor (CAR)-T Cells. Cancer Immunol Res. July 2018 Notes: doi: 10.1158/2326-6066.CIR-17-0405. [Epub ahead of print]

Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ: Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood June 2018 Notes: doi: 10.1182/blood-2018-03-837609. [Epub ahead of print]

Fraietta JA1, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ: Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature May 2018 Notes: doi:10.1038/s41586-018-0178-z.

Fraietta Joseph A, Lacey Simon F, Orlando Elena J, Pruteanu-Malinici Iulian, Gohil Mercy, Lundh Stefan, Boesteanu Alina C, Wang Yan, O'Connor Roddy S, Hwang Wei-Ting, Pequignot Edward, Ambrose David E, Zhang Changfeng, Wilcox Nicholas, Bedoya Felipe, Dorfmeier Corin, Chen Fang, Tian Lifeng, Parakandi Harit, Gupta Minnal, Young Regina M, Johnson F Brad, Kulikovskaya Irina, Liu Li, Xu Jun, Kassim Sadik H, Davis Megan M, Levine Bruce L, Frey Noelle V, Siegel Donald L, Huang Alexander C, Wherry E John, Bitter Hans, Brogdon Jennifer L, Porter David L, June Carl H, Melenhorst J Joseph: Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature medicine 24(5): 563-571, May 2018.

Tanyi Janos L, Bobisse Sara, Ophir Eran, Tuyaerts Sandra, Roberti Annalisa, Genolet Raphael, Baumgartner Petra, Stevenson Brian J, Iseli Christian, Dangaj Denarda, Czerniecki Brian, Semilietof Aikaterini, Racle Julien, Michel Alexandra, Xenarios Ioannis, Chiang Cheryl, Monos Dimitri S, Torigian Drew A, Nisenbaum Harvey L, Michielin Olivier, June Carl H, Levine Bruce L, Powell Daniel J, Gfeller David, Mick Rosemarie, Dafni Urania, Zoete Vincent, Harari Alexandre, Coukos George, Kandalaft Lana E: Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science translational medicine 10(436), April 2018.

Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H: Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI insight 3(8), Apr 2018.

Beatty Gregory L, O'Hara Mark H, Lacey Simon F, Torigian Drew A, Nazimuddin Farzana, Chen Fang, Kulikovskaya Irina M, Soulen Michael C, McGarvey Maureen, Nelson Anne Marie, Gladney Whitney L, Levine Bruce L, Melenhorst J Joseph, Plesa Gabriela, June Carl H: Activity of Mesothelin-specific Chimeric Antigen Receptor T cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. Gastroenterology Mar 2018.

Maude Shannon L, Laetsch Theodore W, Buechner Jochen, Rives Susana, Boyer Michael, Bittencourt Henrique, Bader Peter, Verneris Michael R, Stefanski Heather E, Myers Gary D, Qayed Muna, De Moerloose Barbara, Hiramatsu Hidefumi, Schlis Krysta, Davis Kara L, Martin Paul L, Nemecek Eneida R, Yanik Gregory A, Peters Christina, Baruchel Andre, Boissel Nicolas, Mechinaud Francoise, Balduzzi Adriana, Krueger Joerg, June Carl H, Levine Bruce L, Wood Patricia, Taran Tetiana, Leung Mimi, Mueller Karen T, Zhang Yiyun, Sen Kapildeb, Lebwohl David, Pulsipher Michael A, Grupp Stephan A: Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. The New England journal of medicine 378(5): 439-448, February 2018.

Schuster Stephen J, Svoboda Jakub, Chong Elise A, Nasta Sunita D, Mato Anthony R, Anak Özlem, Brogdon Jennifer L, Pruteanu-Malinici Iulian, Bhoj Vijay, Landsburg Daniel, Wasik Mariusz, Levine Bruce L, Lacey Simon F, Melenhorst Jan J, Porter David L, June Carl H: Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. The New England journal of medicine 377(26): 2545-2554, Dec 2017 Notes: doi: 10.1056/NEJMoa1708566. [Epub ahead of print]

Tchou Julia, Zhao Yangbing, Levine Bruce L, Zhang Paul J, Davis Megan M, Melenhorst Jan Joseph, Kulikovskaya Irina, Brennan Andrea L, Liu Xiaojun, Lacey Simon F, Posey Avery D, Williams Austin D, So Alycia, Conejo-Garcia Jose R, Plesa Gabriela, Young Regina M, McGettigan Shannon, Campbell Jean, Pierce Robert H, Matro Jennifer M, DeMichele Angela M, Clark Amy S, Cooper Laurence J, Schuchter Lynn M, Vonderheide Robert H, June Carl H: Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. Cancer immunology research 5(12): 1152-1161, Dec 2017.

back to top
Last updated: 08/09/2018
The Trustees of the University of Pennsylvania